Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Have you been told you have a condition called ‘Avascular Necrosis’ or ‘Osteonecrosis’? If so, could we talk to you about a new study that is currently being thought about?

Who are we?

We are a team of university researchers, surgeons, rheumatologists and nurses wanting to investigate which drugs might better help people with ‘Avascular Necrosis’ or ‘Osteonecrosis’. 

Who are we looking for?

The National Institute for Health Research is looking to fund a study to decide if one drug or a combination of drugs might improve pain and movement for individuals with these painful conditions.

We would like to invite people who have experienced hip pain due to the above conditions to join us for an informal meeting to talk about the proposed study, and to ask your opinions about the study we are thinking we would run – YOU WOULD NOT BE JOINING OR BE ASKED TO JOIN THE STUDY.

Want to learn more?

Join us for a meeting on Friday 4th September in Oxford at the Botnar Research Centre at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. We will provide light refreshments and will reimburse you for your time and travel.

If you are interested in knowing more and would like to get involved, please call Vicki Barber on  01865 223463 or email vicki.barber@ndorms.ox.ac.uk                                                   

This study is supported by the Patient and Public Involvement Officer, Research Design Service South Central, National Institute for Health Research.

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis

Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.